Accordingly, TMB of ten or more mutations per megabase, MMR deficiency, and MSI-H are currently the only tumour-agnostic FDA-approved biomarkers of response to anti-PD-(L)1 therapy [5–7, 191]. This evidence concerns the gene CD274 and neoplasm.